Sharps Technology, Inc. Announces Pricing of Upsized $20.0 Million Underwritten Public Offering

Core Viewpoint - Sharps Technology, Inc. has announced a public offering expected to raise approximately $20 million, aimed at supporting its operations and working capital needs [1][4]. Offering Details - The offering includes 14,285,714 Common Units, each comprising one share of Common Stock or one Pre-Funded Warrant, along with Series A and Series B Registered Common Warrants, both with an exercise price of$1.75 [2]. - The public offering price per Common Unit is set at $1.40, with Pre-Funded Units priced at$1.3999 [2]. - Aegis Capital Corp. has been granted a 45-day option to purchase additional shares and warrants, up to 15% of the total sold in the offering [3]. Financial Proceeds and Use - The gross proceeds from the offering are anticipated to be around $20 million, with the transaction expected to close on or about January 29, 2025 [4]. - The net proceeds will be utilized for general corporate purposes and working capital [4]. Company Overview - Sharps Technology specializes in innovative medical devices and pharmaceutical packaging, focusing on patented syringe products with advanced safety features [8]. - The company operates a manufacturing facility in Hungary and is collaborating with Nephron Pharmaceuticals to enhance its manufacturing capacity in the U.S. [8].